
Kernal Bio Wins $48M ARPA-H Grant for Affordable In Vivo CAR T-Cell Therapies
Kernal Biologics Secures Up to $48 Million from ARPA-H to Advance In Vivo CAR T-Cell Therapy for Cancer and Autoimmune Diseases Kernal Biologics, Inc., a venture-backed TechBio innovator pioneering next-generation therapeutics that program human cells directly within the body, has…












